Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola - Psychedelic Alpha interview on execution, regulatory rigor, and scaling serotonergic CNS medicines

Helus CEO Michael Cola discusses how specialty-pharma experience can help Helus move serotonergic CNS medicines from development through approval and into real-world use. In a brief Q&A with Psychedelic Alpha’s Josh Hardman, Cola focuses on execution and the need for regulatory rigor while scaling programs intended to deliver differentiated CNS therapies. The conversation frames what leadership priorities matter most for taking psychedelic-linked or serotonergic CNS drug candidates toward commercialization, emphasizing operational discipline and the practical challenges of CNS drug deployment beyond clinical trials.